# Beta Drugs (NSE: BETA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BETA · Pivot · prices to 22 Oct 2026

Beta Drugs (NSE: BETA) closed at ₹1,773.00 on 22 Oct 2026, up 5.60% on the day. With a market capitalisation of ₹1,966 Cr, it ranks 1150th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 43.4× trailing earnings, against a return on equity of 16.9% in FY26. Over the past year the share price has risen 3.3%. Its 52-week range is ₹990.10 (25 Feb 2026) to ₹2,807.90 (12 Aug 2026); the last close is 36.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹126 Cr (+25.3% year on year) and net profit ₹16 Cr (+40.9%), on a consolidated basis. Promoters held 59.10% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,773.00 |
| Market cap | ₹1,966 Cr |
| P/E (trailing) | 43.4 |
| ROE | 16.9% (FY26) |
| ROCE | 18.0% (FY26) |
| Debt to equity | 0.6 |
| 52-week high | ₹2,807.90 (12 Aug 2026) |
| 52-week low | ₹990.10 (25 Feb 2026) |
| 1-year return | +3.3% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹126 Cr | +25.3% | ₹16 Cr | +40.9% | ₹14.78 |
| Q4 FY26 | ₹94 Cr | +0.2% | ₹9 Cr | +0.2% | ₹8.93 |
| Q3 FY26 | ₹87 Cr | −1.2% | ₹9 Cr | −4.8% | ₹8.40 |
| Q2 FY26 | ₹103 Cr | — | ₹12 Cr | — | ₹12.10 |
| Q1 FY26 | ₹100 Cr | — | ₹12 Cr | — | ₹11.59 |
| Q4 FY25 | ₹94 Cr | — | ₹9 Cr | — | ₹8.95 |
| Q3 FY25 | ₹88 Cr | — | ₹9 Cr | — | ₹9.31 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹362 Cr | ₹42 Cr |
| FY24 | ₹296 Cr | ₹36 Cr |
| FY23 | ₹227 Cr | ₹31 Cr |
| FY22 | ₹184 Cr | ₹25 Cr |
| FY21 | ₹116 Cr | ₹12 Cr |
| FY20 | ₹91 Cr | ₹9 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 59.10%
- Foreign institutions: 1.02%
- Domestic institutions: 6.23%
- Non-institutions: 33.65%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Indoco Remedies](https://app.pivotnow.in/stock/INDOCO) | ₹230.55 | ₹2,128 Cr | — | — |
| [Panacea Biotec](https://app.pivotnow.in/stock/PANACEABIO) | ₹335.85 | ₹2,057 Cr | — | — |
| [Sakar Healthcare](https://app.pivotnow.in/stock/SAKAR) | ₹923.90 | ₹2,056 Cr | 67.6 | — |
| [Sai Parenterals](https://app.pivotnow.in/stock/SAIPARENT) | ₹461.90 | ₹2,041 Cr | 103.6 | — |
| [Hester Biosciences](https://app.pivotnow.in/stock/HESTERBIO) | ₹2,165.00 | ₹1,842 Cr | 32 | — |
| [Windlas Biotech](https://app.pivotnow.in/stock/WINDLAS) | ₹885.70 | ₹1,828 Cr | 28.4 | — |

## Questions and answers

### What is the share price of Beta Drugs today?

Beta Drugs (NSE: BETA) last closed at ₹1,773.00 on 22 Oct 2026. Its 52-week high is ₹2,807.90 and its 52-week low is ₹990.10.

### What is the market cap of Beta Drugs?

Beta Drugs' market capitalisation is ₹1,966 Cr (₹1,966 Cr) at the 22 Oct 2026 close, ranking 1150th among the NSE companies Pivot tracks.

### What is the P/E ratio of Beta Drugs?

Beta Drugs trades at a trailing P/E of 43.4. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 67.6.

### What is the ROE and ROCE of Beta Drugs?

Return on equity was 16.9% in FY26 and return on capital employed was 18.0% in FY26 (consolidated figures).

### Is Beta Drugs a debt-free company?

No. Beta Drugs' debt-to-equity ratio was 0.6 in FY26, with total debt of ₹133 Cr.

### What were Beta Drugs' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Beta Drugs reported revenue of ₹126 Cr, +25.3% year on year, and net profit of ₹16 Cr, +40.9% year on year.

### How has Beta Drugs stock performed over the last year?

Beta Drugs' share price has risen 3.3% over the past year, −24.2% over three months and −14.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Beta Drugs?

As of 30 Jun 2026: promoters 59.10%, foreign institutions 1.02%, domestic institutions 6.23%, non-institutions 33.65%.

### Who are Beta Drugs' competitors?

The listed Pharma & Healthcare companies closest to Beta Drugs by market cap are Indoco Remedies, Panacea Biotec, Sakar Healthcare, Sai Parenterals, Hester Biosciences and Windlas Biotech.

### Is Beta Drugs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Beta Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BETA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.